Loading data for TARS — first visit, this takes a few seconds.
Tarsus Pharmaceuticals In... (TARS)
NasdaqGS: TARS
· Real-Time Price · USD
72.70
+1.21 (1.69%)
At close: Aug 21, 2026, 8:00 PM
72.70
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Tarsus Pharmaceuticals Inc. (TARS) Stock Price, Analysis & Data
1.69% (1D)
No data available
| Bid | 51.54 |
| Market Cap | 3.19B |
| Revenue (ttm) | 606.33M |
| Net Income (ttm) | -46.48M |
| 0.51 | |
| -1.07 | |
| n/a | |
| 31.27 | |
| P/B (ttm) | 9.07 |
| P/S (ttm) | 5.26 |
| Earnings Date | Nov 4, 2026 |
| Ask | 92.78 |
| Volume | 560,673 |
| Avg. Volume (20D) | 959,427 |
| Open | 71.72 |
| Previous Close | 71.49 |
| Day's Range | 71.26 - 73.14 |
| 52-Week Range | 48.20 - 85.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal h...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 370
Stock Exchange NasdaqGS
Ticker Symbol TARS
Website https://tarsusrx.com
Financial Performance
In 2025, Tarsus Pharmaceuticals's revenue was 451.36M, an increase of 146.71% compared to the previous year's 182.95M. Earnings were -66.42M, a decrease of -42.52%.
Financial StatementsEarnings Surprise
Tarsus Pharmaceuticals has released their quarterly earnings on Aug 6, 2026:
Tarsus Pharmaceuticals Inc. is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2